Innovating in the Fight against Brain Tumors

Oncolytic Viruses

Manufacturing Oncolytic Viruses: Where Complexity Demands Experience

Mathias Kahl

IDT Biologika

MRD

Measurable Residual Disease Moves Deeper Into Hematologic Cancer Development

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac

Single-Use

The Changing Economics of Single-Use Biomanufacturing

Pharma's Almanac

CDMO Consolidation

How Far Should CDMO Network Consolidation Go?

Pharma's Almanac

Pediatric Oncology

Why Pediatric Oncology Needs Its Own Drug Development Paradigm

David Alvaro, Ph.D.

Pharma's Almanac

Capacity

Is the Bioreactor Arms Race Over?

David Alvaro, Ph.D.

Pharma's Almanac

Partner Selection

How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?

Pharma's Almanac

Chinese Biopharma

Pharmaceutical Innovation in China Takes Center Stage

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics

Vaccine Development

New Vaccine Technologies Expand the Frontiers of Prevention and Treatment

Cynthia A. Challener, Ph.D.

Pharma's Almanac